Posted: Wed Apr 15, 2009 10:43 am Post subject: Preclinical Study: VLP vax protects against H5N1, H1N1
Novavax scientists designed and produced a recombinant virus-like particle (VLP) vaccine candidate against the 1918 H1N1 influenza strain.
"Unlike other non-live influenza vaccines, the VLPs are uniquely positioned to stimulate immunity through multiple mechanisms," said Dr. Penny Heaton, Chief Medical Officer at Novavax.
"First, they contain HA protein that is the same structure as the live virus, which may stimulate HA antibodies of several types that not only prevent the virus from attaching to cells but also prevent the virus from fusing with cells.
Second, the VLPs contain NA which may stimulate production of antibody that prevents spread of the virus down the respiratory tract.
Finally, the structure of the HA and NA proteins and the way in which they are embedded in lipids on the surface of the VLP may activate the innate immune system providing protection against both the H1N1 and H5N1 strains," said Dr. Heaton.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum